Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases
Jiangyan Yong,Hongli Shu,Xiao Zhang,Kun Yang,Guining Luo,Lu Yu,Jiaqi Li,Hong Huang
DOI: https://doi.org/10.2147/ijn.s451206
IF: 7.033
2024-02-23
International Journal of Nanomedicine
Abstract:Jiangyan Yong, 1, &ast Hongli Shu, 1, &ast Xiao Zhang, 2, &ast Kun Yang, 3 Guining Luo, 3 Lu Yu, 3 Jiaqi Li, 3 Hong Huang 4 1 Department of Clinical Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, People's Republic of China; 2 Department of Clinical Laboratory, Chengdu Children Special Hospital, Chengdu, Sichuan, 610031, People's Republic of China; 3 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People's Republic of China; 4 Department of Clinical Laboratory, the People's Hospital of Chongqing Liang Jiang New Area, Chongqing, 401121, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hong Huang, Email Given the unique physiological and pathological characteristics of the lung, the direct, inhalable route is more conducive to pulmonary drug delivery and disease control than traditional systemic drug delivery, significantly circumventing drug loss, off-target effects, systemic and organ toxicity, etc., and is widely regarded as the preferred regimen for pulmonary drug delivery. However, very few lung diseases are currently treated with the preferred inhaled formulations, such as asthma, chronic obstructive pulmonary disease and pulmonary hypertension. And there is a lack of appropriate inhaled formulations for other critical lung diseases, such as lung cancer and pulmonary fibrosis, due to the fact that the physicochemical properties of the drugs and their pharmacokinetic profiles do not match the physiology of the lung, and conventional inhalation devices are unable to deliver them to the specific parts of the lung. Phytochemicals of natural origin, due to their wide availability and clear safety profile, hold great promise for the preparation of inhalable formulations to improve the current dilemma in the treatment of lung diseases. In particular, the preparation of inhalable formulations based on nano- and microparticulate carriers for drug delivery to deep lung tissues, which overcome the shortcomings of conventional inhalation therapies while targeting the drug activity directly to a specific part of the lung, may be the best approach to change the current dilemma of lung disease treatment. In this review, we discuss recent advances in nano- and micron-carrier-based inhalation formulations for the delivery of natural products for the treatment of pulmonary diseases, which may represent an opportunity for practical clinical translation of natural products. Keywords: inhaled nanoformulations, inhalation therapy, natural products, nanomedicine, pulmonary diseases Globally, pulmonary diseases, represented by acute respiratory infections, chronic obstructive pulmonary disease (COPD), bronchial asthma, and lung cancer, are characterized by high morbidity, mortality, disability, and treatment costs. 1 With changing lifestyles, increasing environmental pollution, unavoidable occupational exposures, the continued prevalence of tobacco use, and an aging population, the morbidity, mortality and associated disease burden of pulmonary disease are increasing year by year. There is an urgent need to discover new therapeutic approaches applicable to the physiology, pathology and anatomy of the lung to transform the current global public health challenge of preventing and treating pulmonary disease. 1,2 Conventional modes of drug delivery inevitably limit efficacy due to degradation of the active fraction in the gastrointestinal tract or first-pass metabolism in the liver, and this systemic mode of drug delivery increases non-specific toxicity due to high drug exposure to other organs. 3 The lung is an excellent organ for drug absorption. Given its natural advantages, such as its large absorptive surface area (100–200 m 2 ), abundant capillaries, very short transit distance, thin alveolar epithelial layer, and slow cell surface clearance, inhalation therapy is widely recognized as the preferred regimen for pulmonary drug delivery. 4 Pulmonary delivery devices, such as dry powder inhalers (DPIs), pressurized metered dose inhalers (PMDIs), nebulizers, etc., are able to deliver medications locally to the lungs, dramatically improving the bioavailability of medications while fully exploiting their efficacy. 5,6 Currently, inhaled formulations have become the first-line treatment for asthma and COPD, but there are no corresponding inhaled formulations for other lung diseases, including lung cancer and pulmonary fibrosis. Phytochemicals of natural origin hold promise for inhaled formulations to improve the current dilemma of lung disease treatment due to their w -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology